- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patent holdings for IPC class C07K 16/00
Total number of patents in this class: 11386
10-year publication summary
|
903
|
877
|
815
|
881
|
824
|
772
|
720
|
574
|
450
|
224
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4246 |
267 |
| Amgen Inc. | 4074 |
255 |
| Genentech, Inc. | 3975 |
204 |
| F. Hoffmann-La Roche AG | 7929 |
163 |
| Chugai Seiyaku Kabushiki Kaisha | 1349 |
159 |
| Hoffmann-La Roche Inc. | 3405 |
143 |
| The Regents of the University of California | 19868 |
130 |
| Novartis AG | 10867 |
101 |
| Abbvie Inc. | 1803 |
95 |
| Xencor, Inc. | 396 |
83 |
| Bristol-myers Squibb Company | 4878 |
68 |
| Pfizer Inc. | 3379 |
67 |
| Janssen Biotech, Inc. | 1546 |
66 |
| Ablynx N.V. | 395 |
64 |
| Zymeworks Inc. | 256 |
59 |
| MedImmune, LLC | 492 |
58 |
| Sanofi | 4038 |
58 |
| Cytiva BioProcess R&D AB | 304 |
57 |
| Genzyme Corporation | 1241 |
54 |
| SeaGen Inc | 586 |
52 |
| Other owners | 9183 |